An inquest in Norfolk, England, is examining whether a rise in the dose of the weight‑loss medication Mounjaro contributed to the death of Caroline Savage, 73, who died in October 2024 after developing a perforated intestine that led to fecal peritonitis.
Sudden illness after dose increase
Savage had been privately prescribed Mounjaro for about four months, according to materials presented at the coroner’s hearing. The medication, part of a class of drugs that can cause gastrointestinal side effects, was being used to address weight issues and symptoms associated with lipedema. After an interim review of her treatment she was advised to finish the remaining 7.5 mg doses in her pen before moving up to a 10 mg dose.
On the morning of Oct. 18, Savage developed intense, unrelenting abdominal pain. Emergency services were called at about 1:30 p.m. and she was taken to the Norfolk and Norwich Hospital’s rapid assessment and treatment area. She died the next day, Oct. 19, from fecal peritonitis — the result of a perforation in part of her intestines.
Family questions clinical response
The coroner’s court has been asked to consider the extent to which the drug may have been a factor in the fatal course. Savage’s family — represented in the hearing by barrister Jasmine Leng — told the inquest they were concerned that clinicians caring for her in hospital may have too readily attributed her symptoms to known side effects of the medication and so missed the opportunity for further investigation.
"She was warned that possible side effects included abdominal pain and constipation."
The quote above, given in evidence by the privately prescribing doctor, was part of the account that Savage had been informed about potential adverse effects. The family’s position is that the doctors who later treated her should have pursued more diagnostic tests rather than assume the symptoms were drug‑related.
Clinical context and questions for the inquest
Mounjaro, a medication that has gained attention for weight management, is known to cause gastrointestinal symptoms in some patients. The inquest is focusing on whether the timing of Savage’s dose change and the progression of her symptoms point to a causal link, and whether the in‑hospital response met clinical expectations for investigating acute abdominal pain in an older patient.
Legal counsel for the family argued that the sudden and severe nature of Savage’s pain on Oct. 18 should have triggered further diagnostic steps rather than being attributed to typical side effects. The hearing will therefore consider medical records, clinician testimony and the prescribing history to reach conclusions about avoidability and whether any lessons should be learned about recognition of severe complications.
Timeline at a glance
| When | Event |
|---|---|
| July 2024 | Weight recorded at 128 kg (282 lb) |
| Before Oct. 2024 | Prescribed Mounjaro; taking 7.5 mg doses |
| Oct. 2024 | Weight recorded at 114 kg (251 lb); advised to increase to 10 mg |
| Oct. 18, 2024 | Onset of acute, constant abdominal pain; ambulance called at about 1:30 p.m. |
| Oct. 19, 2024 | Died from fecal peritonitis due to intestinal perforation |
Broader implications
The case is unfolding against a backdrop of heightened public and medical interest in medications used for weight loss. As these drugs are increasingly prescribed, questions about monitoring, dose adjustments and early recognition of serious complications become more pressing. The coroner’s findings could inform guidance on how prescribers and emergency clinicians manage patients on such treatments when they present with abdominal symptoms.
For families and patients, the hearing underlines the importance of clear communication about potential side effects and the need for medical teams to weigh those possibilities alongside other diagnoses, especially when symptoms escalate acutely.
- Key medical facts: Cause of death recorded as fecal peritonitis from intestinal perforation.
- Medication timeline: Several months on Mounjaro, with an advised increase from 7.5 mg to 10 mg shortly before the event.
- Central legal question: Whether clinicians dismissed treatable causes by too quickly attributing symptoms to drug side effects.
The inquest continues as investigators and family representatives seek to understand all the clinical decisions and events that led to Savage’s death.
